MCID: NNL002
MIFTS: 56

Nonalcoholic Steatohepatitis

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 49 24 69
Non-Alcoholic Fatty Liver Disease 49 24 69
Nonalcoholic Fatty Liver Disease 24 36
Non-Alcoholic Steatohepatitis 49 24
Fatty Liver 24 69
Nash 49 24
Fatty Degeneration 69
Steatohepatitis 69
Steatosis 24
Nafld 24

Classifications:



External Ids:

KEGG 36 H01333

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 49 Nonalcoholic steatohepatitis, or NASH, is a common, often “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear. Last updated: 2/24/2012

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic fatty liver disease, is related to hepatitis and lipodystrophy, familial partial, type 2. An important gene associated with Nonalcoholic Steatohepatitis is NAFLD2 (Fatty Liver Disease, Nonalcoholic, Susceptibility To, 2), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Genetics Home Reference : 24 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

Wikipedia : 72 Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when fat is... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.2 F2 GPT SLC17A5 TNF
2 lipodystrophy, familial partial, type 2 30.4 INS LEP
3 lipodystrophy 30.4 ADIPOQ INS LEP
4 acanthosis nigricans 30.3 ADIPOQ INS LEP
5 morbid obesity 30.2 ADIPOQ INS LEP RETN
6 cryptogenic cirrhosis 30.1 F2 HFE KRT18
7 apnea, obstructive sleep 30.0 ADIPOQ IL6 INS LEP TNF
8 sleep apnea 30.0 ADIPOQ IL6 INS LEP TNF
9 portal hypertension 30.0 F2 GPT TNF
10 hepatitis b 30.0 F2 GPT SLC17A5 TNF
11 chronic kidney failure 29.9 IL6 INS LEP
12 alcoholic liver cirrhosis 29.6 F2 PNPLA3 SLC17A5 TNF
13 alcoholic hepatitis 29.6 F2 GPT IL6 KRT18 SLC17A5 TNF
14 fatty liver disease 29.6 ADIPOQ GPT HFE IL6 INS KRT18
15 diabetes mellitus 29.3 ADIPOQ HFE IL6 INS LEP TNF
16 viral hepatitis 29.1 F2 GPT HFE KRT18 SLC17A5 TNF
17 liver cirrhosis 29.1 ADIPOQ F2 GPT HFE KRT18 SLC17A5
18 body mass index quantitative trait locus 11 29.0 ADIPOQ GPT IL6 INS LEP PNPLA3
19 liver disease 28.0 ADIPOQ F2 GPT HFE IL6 INS
20 visceral steatosis 12.1
21 visceral steatosis, congenital 11.9
22 fibrosis of extraocular muscles, congenital, 1 10.7
23 body mass index quantitative trait locus 12 10.7
24 body mass index quantitative trait locus 14 10.7
25 body mass index quantitative trait locus 9 10.7
26 body mass index quantitative trait locus 18 10.7
27 body mass index quantitative trait locus 8 10.7
28 body mass index quantitative trait locus 7 10.7
29 body mass index quantitative trait locus 4 10.7
30 body mass index quantitative trait locus 10 10.7
31 paraquat poisoning 10.5 GPT SLC17A5
32 hepatocellular carcinoma 10.5
33 pyridoxine deficiency 10.5 GPT SLC17A5
34 hepatitis c 10.4
35 scorpion envenomation 10.4 IL6 TNF
36 fascioliasis 10.4 GPT INS SLC17A5
37 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 INS LEP
38 adult dermatomyositis 10.4 GPT TNF
39 abdominal obesity-metabolic syndrome 1 10.4 ADIPOQ INS LEP
40 scrub typhus 10.4 GPT SLC17A5 TNF
41 nontuberculous mycobacterial lung disease 10.4 ADIPOQ LEP TNF
42 choline deficiency disease 10.4
43 endocrine pancreas disease 10.4 ADIPOQ INS LEP
44 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
45 malignant otitis externa 10.4 F2 INS
46 burns 10.4 INS TNF
47 critical limb ischemia 10.4 IL6 TNF
48 streptococcal toxic-shock syndrome 10.3 IL6 TNF
49 aging 10.3
50 hepatoportal sclerosis 10.3 F2 GPT

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 PPARA IL6 INS ADIPOQ F2 LEP
2 growth/size/body region MP:0005378 10.14 PPARA IL6 INS ADIPOQ KRT18 F2
3 adipose tissue MP:0005375 10.03 PPARA IL6 INS ADIPOQ LEP RETN
4 immune system MP:0005387 10.02 PPARA IL6 INS ADIPOQ F2 LEP
5 integument MP:0010771 9.86 PPARA IL6 INS ADIPOQ F2 LEP
6 liver/biliary system MP:0005370 9.85 PPARA IL6 RETN INS ADIPOQ KRT18
7 mortality/aging MP:0010768 9.7 PPARA IL6 INS ADIPOQ KRT18 F2
8 skeleton MP:0005390 9.23 IL6 INS ADIPOQ F2 GPT LEP

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
4
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
5
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
6
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Ribavirin Approved Phase 4 36791-04-5 37542
9
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
10
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
11
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
12
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
13
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
14
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
15
Empagliflozin Approved Phase 4 864070-44-0
16 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-02-9 14985
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
19 insulin Phase 4,Phase 3,Phase 2,Phase 1
20 interferons Phase 4
21 diuretics Phase 4,Phase 2
22 Micronutrients Phase 4,Phase 3,Phase 2
23 Sodium Chloride Symporter Inhibitors Phase 4
24 Natriuretic Agents Phase 4,Phase 2
25 Tocopherols Phase 4,Phase 3,Phase 2
26 Tocotrienols Phase 4,Phase 3,Phase 2
27 Trace Elements Phase 4,Phase 3,Phase 2
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
29 Hormones Phase 4,Phase 2,Phase 3,Phase 1
30 Vitamins Phase 4,Phase 3,Phase 2
31 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
32 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
33 Angiotensinogen Phase 4,Phase 3,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
35 Anticholesteremic Agents Phase 4,Phase 2,Phase 1
36 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antihypertensive Agents Phase 4,Phase 3,Phase 2
40 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
41 Interferon-alpha Phase 4
42 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1
43 Protective Agents Phase 4,Phase 3,Phase 2
44 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
46 Antioxidants Phase 4,Phase 3,Phase 2
47 Antiviral Agents Phase 4,Phase 3,Phase 2
48 rifamycin SV Phase 4
49 Rifamycins Phase 4
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 297)

# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
3 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
6 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
7 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
8 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
9 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
10 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
11 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
12 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
13 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
14 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
15 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
16 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
17 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
18 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
19 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
20 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
21 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
22 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
23 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
24 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
25 Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis Completed NCT00820651 Phase 3
26 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
27 Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Completed NCT00509418 Phase 3
28 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
29 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
30 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
31 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
32 Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
33 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
34 The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
35 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
36 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
37 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
38 DHA and Vitamin D in Children With Biopsy-proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
39 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
40 Development of a Breath Test for Monitoring Patients With Liver Disease Completed NCT00244569 Phase 3 13C-Methacetin
41 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3 Recombinant GH Saizen (Merck-Serono)
42 Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT00655018 Phase 2, Phase 3
43 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Recruiting NCT02541045 Phase 3 metadoxine
44 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3 Elafibranor;Placebo
45 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
46 Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Recruiting NCT03053050 Phase 3 SEL;Placebo
47 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Recruiting NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo
48 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Recruiting NCT02654665 Phase 3 Liraglutide
49 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Recruiting NCT03028740 Phase 3 Cenicriviroc;Placebo
50 Hydroxytyrosol and Vitamin E in Pediatric NASH Recruiting NCT02842567 Phase 3 Hydroxytyrosol plus Vitamin E;Placebo

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

38
Liver, Testes, Heart, Spleen, Endothelial, Bone, Kidney

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 810)
# Title Authors Year
1
Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. ( 29128353 )
2018
2
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. ( 29367468 )
2018
3
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. ( 29406435 )
2018
4
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. ( 29381754 )
2018
5
Organic Solute Transporter OSTI+/A9 is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. ( 29420067 )
2018
6
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. ( 29291351 )
2018
7
A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. ( 29311502 )
2018
8
Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. ( 29404772 )
2018
9
Metabolic Syndrome is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis. ( 29402822 )
2018
10
Haptoglobin Genotype and VitaminA E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. ( 29411270 )
2018
11
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. ( 29375204 )
2018
12
Relationship between intestinal flora and inflammatory factors in patients with nonalcoholic steatohepatitis. ( 29399077 )
2018
13
Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. ( 29424123 )
2018
14
Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. ( 29298863 )
2018
15
Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. ( 29299759 )
2018
16
Nonalcoholic steatohepatitis: the new frontier for liver transplantation. ( 29356708 )
2018
17
Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. ( 29341352 )
2018
18
Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. ( 29401710 )
2018
19
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. ( 28218919 )
2017
20
Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. ( 28472039 )
2017
21
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. ( 28845983 )
2017
22
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
23
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. ( 28823616 )
2017
24
Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. ( 28912806 )
2017
25
Function of inhibitor of Bruton's tyrosine kinase isoform I+ (IBTKI+) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response. ( 28710282 )
2017
26
Oral Supplementation of Glutamine Attenuates the Progression of Nonalcoholic Steatohepatitis in C57BL/6J Mice. ( 28931589 )
2017
27
Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines. ( 28875689 )
2017
28
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. ( 28878132 )
2017
29
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. ( 28875318 )
2017
30
The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial. ( 28892558 )
2017
31
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. ( 28912902 )
2017
32
Erratum: Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. ( 28845609 )
2017
33
Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. ( 28869588 )
2017
34
Caspase 3, 6, 8, and 9 Gene Expression in Peripheral Blood Leukocytes and Plasma Concentrations of IL-6 and TNF-I+ in Carriers of Different Polymorphic Marker -174G>C Genotypes of IL6 Gene Associated with the Risk of Nonalcoholic Steatohepatitis. ( 28091912 )
2017
35
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis. ( 28067690 )
2017
36
Treating Nonalcoholic Steatohepatitis (NASH) in Children: Not a Cinch Task. ( 28073147 )
2017
37
The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. ( 27922486 )
2017
38
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. ( 27797398 )
2017
39
Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. ( 28936971 )
2017
40
Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. ( 28941597 )
2017
41
Nonalcoholic steatohepatitis in children with severe obesity: A global concern. ( 28935179 )
2017
42
Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis. ( 28951310 )
2017
43
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. ( 28079667 )
2017
44
Global Deletion of Glutathione S-Transferase A4 Exacerbates Developmental Nonalcoholic Steatohepatitis. ( 27998724 )
2017
45
Growth arrest and DNA damage-inducible 45I+ protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet. ( 28844958 )
2017
46
A Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis. ( 28051796 )
2017
47
Hepatic vagus nerve regulates Kupffer cell activation via I+7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. ( 28044208 )
2017
48
Gd-EOB-DTPA-enhanced T1I8 imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. ( 29278765 )
2017
49
Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. ( 28886741 )
2017
50
Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. ( 29404480 )
2017

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

Pathways related to Nonalcoholic Steatohepatitis according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 ADIPOQ IL6 INS LEP RETN TNF
2
Show member pathways
12.07 F2 IL6 INS TNF
4 11.77 IL6 LEP TNF
5
Show member pathways
11.71 IL6 INS PPARA TNF
6 11.68 IL6 INS SQSTM1
7
Show member pathways
11.62 ADIPOQ INS TNF
8 11.6 ADIPOQ IL6 INS LEP
9 11.35 ADIPOQ IL6 INS LEP PNPLA3 PPARA
10 11.3 ADIPOQ LEP PPARA TNF
11 10.8 IL6 TNF
12 10.7 GPT INS
13 10.6 ADIPOQ IL6 LEP TNF

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 ADIPOQ F2 GPT HFE IL6 INS

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 glucose homeostasis GO:0042593 9.78 ADIPOQ INS LEP
2 positive regulation of MAPK cascade GO:0043410 9.75 IL6 INS LEP
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 ADIPOQ IL6 INS
4 response to insulin GO:0032868 9.7 LEP PPARA RETN
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 F2 INS LEP
6 response to glucocorticoid GO:0051384 9.67 ADIPOQ IL6 TNF
7 positive regulation of protein phosphorylation GO:0001934 9.67 ADIPOQ F2 SQSTM1 TNF
8 positive regulation of chemokine production GO:0032722 9.65 IL6 TNF
9 positive regulation of JAK-STAT cascade GO:0046427 9.65 IL6 LEP
10 negative regulation of lipid catabolic process GO:0050995 9.64 INS TNF
11 regulation of protein secretion GO:0050708 9.64 INS TNF
12 positive regulation of cellular protein metabolic process GO:0032270 9.63 ADIPOQ INS
13 positive regulation of long-term synaptic potentiation GO:1900273 9.63 INS SQSTM1
14 leukocyte tethering or rolling GO:0050901 9.62 LEP TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.62 SQSTM1 TNF
16 glucose metabolic process GO:0006006 9.62 ADIPOQ INS LEP TNF
17 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.61 SQSTM1 TNF
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.61 IL6 RETN TNF
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.6 ADIPOQ PPARA
20 negative regulation of gluconeogenesis GO:0045721 9.59 ADIPOQ INS
21 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 INS LEP
22 negative regulation of fat cell differentiation GO:0045599 9.58 ADIPOQ IL6 TNF
23 negative regulation of glucose import GO:0046325 9.57 LEP TNF
24 negative regulation of appetite GO:0032099 9.55 LEP PPARA
25 positive regulation of peptide hormone secretion GO:0090277 9.54 HFE INS
26 regulation of receptor activity GO:0010469 9.5 ADIPOQ F2 IL6 INS LEP RETN
27 negative regulation of receptor binding GO:1900121 9.48 ADIPOQ HFE
28 negative regulation of feeding behavior GO:2000252 9.46 INS RETN
29 acute-phase response GO:0006953 9.46 F2 HFE IL6 INS
30 negative regulation of lipid storage GO:0010888 9.43 IL6 LEP TNF
31 positive regulation of STAT protein import into nucleus GO:2000366 8.8 F2 IL6 LEP

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....